Revenue: $3.9 billion, up 5% year-over-year. Adjusted EBITDA: Increased by 3%. Non-GAAP EPS: $0.52, up 8%. Innovative Brands Sales: $589 million, a 45% increase over last year. AUSTEDO Sales: Grew 39% globally, with US business up 40%. AJOVY Sales: Increased by 26% globally. UZEDY Sales: Doubled to $39 million. Generic Business Growth: Up 3% year-over-year. Gross Margin: Non-GAAP gross margin grew by 140 basis points to 52.8%. Net Debt: $15 billion, with net debt-to-EBITDA just over three times. Free Cash Flow: Guidance reflects a slight decrease compared to 2024. 2025 Revenue Guidance: Revised to $16.8 billion to $17.2 billion. Operating Margin Target: 30% by 2027. Net Savings Target: $700 million by 2027.

Warning! GuruFocus has detected 2 Warning Signs with TEVA.

Release Date: May 07, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported its ninth consecutive quarter of growth, with revenue up 5% to $3.9 billion. Innovative brands AUSTEDO, AJOVY, and UZEDY showed strong performance, with AUSTEDO growing 39% globally. The company is on track to achieve a 30% operating margin by 2027, driven by cost optimization and strategic capital allocation. Teva's Biosimilar business is expanding, with two new products launched in the US and more expected by 2027. The company is transforming from a pure-play Generics company to a leading biopharmaceutical company, focusing on innovative products and pipeline development.

Negative Points

The Generic business growth slowed to 3% due to prior comparisons and inflationary slowdowns in international and European markets. Teva faces potential challenges from US tariffs, although they have been absorbed in the 2025 guidance. The company anticipates a revenue cliff from Generic Revlimid in 2026, which may impact financial performance. Net debt increased by $500 million due to cash distribution related to the Japan business closure and exchange rate fluctuations. There is uncertainty regarding the impact of new US tariffs and the potential need for governmental subsidies to mitigate cost increases.

Q & A Highlights

Q: Can you clarify Teva's strategic direction between being a Generics powerhouse and transitioning to a global biopharma company? Also, is the $700 million in savings a final goal or just a step in a longer journey? A: Richard Francis, CEO: Teva is on a journey from being a pure-play Generics company to a leading biopharmaceutical company. The Generics business remains a crucial part of our strategy, providing discipline and fueling innovation. The $700 million savings is part of an ongoing journey, not a final destination, as we continuously seek cost efficiencies to support long-term growth.

Story Continues

Q: What is Teva's perspective on the Section 232 investigation into pharma and the potential need for governmental subsidies to address overreliance on critical medicines? Also, how does AUSTEDO's pricing in Israel compare to the US? A: Richard Francis, CEO: Teva has mitigated current tariff impacts and is prepared for potential changes. With a strong US manufacturing footprint and limited reliance on China and India, Teva is well-positioned. Regarding AUSTEDO, we have limited sales outside the US, so international pricing has minimal impact on our strategy.

Q: Should we expect EBITDA to be flat in 2026 compared to 2025, given the offsetting of Generic Revlimid impacts? Also, why did net debt increase by $500 million? A: Richard Francis, CEO: EBITDA will increase in absolute dollars and percentage terms in 2026. Eli Kalif, CFO: The net debt increase was due to cash distribution related to the Japan business closure and FX impacts, reducing our cash balance temporarily.

Q: How does Teva plan to handle potential tariff scenarios, and can you elaborate on the cost optimization strategy? A: Richard Francis, CEO: Teva has mitigated current tariffs and planned for potential changes. Cost optimization focuses on rationalizing manufacturing, reducing G&A and TGO costs, and reallocating resources to growth areas like R&D and sales, ensuring continued investment in the business.

Q: Can you discuss the dynamics of the Biosimilar market and the potential impact of new anti-cell therapeutics on your LAI portfolio? A: Richard Francis, CEO: The Biosimilar market dynamics remain steady, with differences between the US and Europe. Our portfolio will drive growth globally. For LAIs, while new therapies are welcome, proven efficacy and safety are crucial, and our products like UZEDY and olanzapine LAI are well-positioned in the market.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments